Table 4. Clinical trials with iodine I... | American Society of Hematology

Table 4.

Clinical trials with iodine I 131 tositumomab

Investigators	Phase	No. of patients	CR/Cru, %	RR, %	PFS^4-150
Kaminski et al⁴⁹	2	59	34	71	12 mo
Vose et al⁵¹	2	47	32	57	11.6 mo
Kaminski et al⁵²	2	60	20	65	8.4 mo
Horning et al⁵³^‡	2	21	14	57	19 mo
Gockerman et al⁵⁴	^4-153	273	27	58	NR
Kaminski et al⁵⁵^4-151	2	76	63	97	68% (at 3 y)

Investigators	Phase	No. of patients	CR/Cru, %	RR, %	PFS^4-150
Kaminski et al⁴⁹	2	59	34	71	12 mo
Vose et al⁵¹	2	47	32	57	11.6 mo
Kaminski et al⁵²	2	60	20	65	8.4 mo
Horning et al⁵³^‡	2	21	14	57	19 mo
Gockerman et al⁵⁴	^4-153	273	27	58	NR
Kaminski et al⁵⁵^4-151	2	76	63	97	68% (at 3 y)

RR indicates response rate; PFS, progression-free survival; and NR, not reached.

Responding patients.

Previously untreated.

Rituximab failures.

Expanded access protocol.